Search

Search Results

• Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer Efficacia della combinazione lapatinib-capecitabina in una paziente con metastasi plurime da carcinoma mammario HER2-positivo

  Maria Moritti, Evaristo Maiello

  50-54

  2018-06-27

  DOI: https://doi.org/10.19156/abtpn.2018.0040

• Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib Paziente con carcinoma mammario metastatico, HER2-positivo, resistente a trastuzumab e pertuzumab ma responsivo a lapatinib

  Daniela Cianniello, Roberta Caputo

  66-68

  2018-06-27

  DOI: https://doi.org/10.19156/abtpn.2018.0044

• Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs Risposta alla combinazione Lapatinib-Capecitabina in giovane paziente con recidiva di carcinoma della mammella HER2-positivo refrattario a due linee di terapia con farmaci anti-HER2

  Clementina Savastano, Fortuna Lombardi

  162-165

  2018-10-12

  DOI: https://doi.org/10.19156/abtpn.2018.0067

• Lapatinib and capecitabine efficacy at systemic and encephalic level in a patient progressed after dual block of HER2 by trastuzumab and pertuzumab and after T-DM1 Efficacia di lapatinib e capecitabina a livello sistemico ed encefalico in una paziente progredita al doppio blocco di HER2 con trastuzumab e pertuzumab e a T-DM1

  Andrea Fontana

  46-49

  2018-06-27

  DOI: https://doi.org/10.19156/abtpn.2018.0039

• Efficacia della combinazione lapatinib-capecitabina in una paziente con carcinoma mammario HER2-positivo metastatico e con resistenza primaria a due linee di terapia con agenti anti-HER2

  Claudio Vernieri, Pietro Indelicato, Giuseppe Capri

  125-129

  2017-12-29

  DOI: https://doi.org/10.19156/abtpn.2017.0029

• Systemic control and encephalic response with lapatinib plus capecitabine as second-line therapy in HER2-positive, metastatic breast cancer Controllo sistemico e risposta encefalica con lapatinib più capecitabina in II linea di terapia nel carcinoma mammario HER2-positivo, metastatico

  Raffaele Ardito, Fiorella Restaino Marino

  110-115

  2018-09-13

  DOI: https://doi.org/10.19156/abtpn.2018.0055

• Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer Lapatinib e capecitabina in III linea in donna giovane affetta da carcinoma mammario avanzato

  Michela Donadio

  35-38

  2018-06-27

  DOI: https://doi.org/10.19156/abtpn.2018.0037

• Efficacy of second-line treatment with capecitabine and lapatinib in HER2-positive mammary neoplasia, with encephalic metastasis, after first-line therapy with dual anti-HER2 block Efficacia in II linea del trattamento con capecitabina e lapatinib nella neoplasia mammaria HER2-positiva, con metastasi encefaliche, dopo I linea con do 

  Tea Zeppola

  62-65

  2018-06-27

  DOI: https://doi.org/10.19156/abtpn.2018.0043

• HER2-positive breast cancer with brain metastasis: long-lasting response after lapatinib treatment Carcinoma mammario HER2-positivo con metastasi cerebrali: risposta prolungata dopo trattamento con lapatinib

  Alessia D'Alonzo, Claudia Bighin

  32-34

  2018-06-27

  DOI: https://doi.org/10.19156/abtpn.2018.0036

• Sopravvivenza a lungo termine in paziente trattata con lapatinib e capecitabina

  Carlo Mulas

  108-111

  2017-12-29

  DOI: https://doi.org/10.19156/abtpn.2017.0025